Trastuzumab (Herceptin) targets the HER2 receptor overexpressed in approximately 15–20% of breast cancers and a subset of gastric cancers. It is used in the adjuvant, neo-adjuvant and metastatic settings. At our centre, HER2 status is confirmed by IHC 3+ or FISH amplification before initiation. Trastuzumab is typically given 3-weekly for one year in early breast cancer (with chemotherapy), and until disease progression in the metastatic setting. Cardiac monitoring (ECHO/MUGA scan) is performed before and during treatment, as Trastuzumab can affect left ventricular function. Pertuzumab (dual HER2 blockade) and T-DM1 (antibody-drug conjugate) are used in appropriate settings for enhanced HER2-targeted treatment.
📋 Treatment Overview
Type
Trastuzumab (Herceptin) Therapy — HER2+ Cancer
Speciality
Oncology & Haematology
Administered By
Dr. Ravindra Joshi
📅 Schedule a Consultation
Talk to Dr. Joshi about whether this treatment is right for you. OPD: Mon–Thu, 10 AM – 1 PM.